Agios Pharmaceuticals Announces Proposed Offering of Common Stock

CAMBRIDGE, Mass.--()--Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) today announced that it has commenced an underwritten public offering of 2,000,000 shares of its common stock. All of the shares in the offering are to be sold by Agios. Agios intends to grant the underwriters a 30-day option to purchase up to an additional 300,000 shares of common stock sold in the offering. The proceeds of the offering are expected to be used to fund the company’s clinical and research development activities. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.

J.P. Morgan Securities LLC and Goldman, Sachs & Co. are acting as joint book-running managers for the offering. Cowen and Company, LLC and Leerink Partners LLC are serving as co-managers.

A registration statement on Form S-1 relating to the securities proposed to be sold in this offering has been filed with the Securities and Exchange Commission but has not yet become effective. The securities may not be sold nor may offers to buy be accepted prior to the time that the registration statement becomes effective.

The securities described in this release are being offered only by means of a prospectus. A copy of the preliminary prospectus can be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 866-803-9204; or Goldman, Sachs, & Co., Attn: Prospectus Department, 200 West Street, New York, NY 10282, telephone: 866-471-2526, facsimile: 212-902-9316, e-mail: prospectus-ny@ny.email.gs.com.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals is focused on discovering and developing novel drugs to treat cancer and inborn errors of metabolism, or IEMs, which are rare genetic metabolic diseases, through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has multiple first-in-class lead product candidates in cancer metabolism and IEMs in clinical and/or preclinical development.

Contacts

Agios Pharmaceuticals, Inc.
Lora Pike, Senior Director, Investor Relations and Public Relations
617-649-8608, Lora.pike@agios.com

Sharing

Contacts

Agios Pharmaceuticals, Inc.
Lora Pike, Senior Director, Investor Relations and Public Relations
617-649-8608, Lora.pike@agios.com